REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Historical Holders from Q1 2014 to Q3 2025

Symbol
REGN on Nasdaq
CUSIP
75886F107
Type / Class
Equity / COMMON STOCK
Shares outstanding
105M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
86.7M
Holdings value
$48.8B
% of all portfolios
0.032%
Grand Portfolio weight change
-0.002%
Number of holders
1196
Number of buys
620
Number of sells
-516
Average Value change %
+0%
Average buys %
+0.009%
Average sells %
-0.006%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JPMORGAN CHASE & CO 4.4% -14% $2.73B -$463M 4.74M -14.5% JPMORGAN CHASE & CO. May 30, 2025
FMR LLC 3.2% -55% $1.93B -$2.78B 3.36M -59% FMR LLC Jun 30, 2025

Institutional Holders of REGENERON PHARMACEUTICALS, INC. - COMMON STOCK (REGN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 86.7M $48.8B -$1.23B $562.27 1,196
2025 Q2 89.1M $46.8B -$1.42B $525.00 1,189
2025 Q1 92M $58.3B -$1.19B $634.23 1,271
2024 Q4 93M $66.3B +$312M $712.33 1,286
2024 Q3 91.4M $95.8B -$2.79B $1,051.24 1,365
2024 Q2 93.9M $98.7B +$2.5B $1,051.03 1,315
2024 Q1 91.6M $88B +$1.17B $962.49 1,293
2023 Q4 730K $641M -$146M $878.29 17
2023 Q3 89.9M $74B -$573M $822.96 1,149
2023 Q2 90.7M $65.3B -$2.75B $718.54 1,138
2023 Q1 90.4M $74.2B -$1.22B $821.67 1,158
2022 Q4 91.3M $65.8B -$200M $721.49 1,127
2022 Q3 91.7M $63.2B -$160M $688.87 1,043
2022 Q2 93M $54.9B +$596M $591.13 1,037
2022 Q1 82.2M $57.4B +$1.53B $698.42 1,061
2021 Q4 69.9M $44.1B +$442M $631.52 1,047
2021 Q3 69.5M $42B +$478M $605.18 991
2021 Q2 79.7M $44.5B -$28.9M $558.54 947
2021 Q1 89.4M $42.2B -$353M $473.14 902
2020 Q4 89.5M $43.2B -$836M $483.11 879
2020 Q3 89.8M $50.3B -$627M $559.78 888
2020 Q2 90.6M $56.5B +$10.7B $623.65 912
2020 Q1 73.8M $36B +$992M $488.29 786
2019 Q4 73.1M $27.5B +$184M $375.48 677
2019 Q3 72.8M $20.2B -$57M $277.40 603
2019 Q2 73.6M $23B +$181M $313.00 640
2019 Q1 72.4M $29.7B -$48.4M $410.62 692
2018 Q4 73M $27.3B -$163M $373.50 648
2018 Q3 73.3M $29.6B +$479M $404.04 623
2018 Q2 72.2M $24.9B +$363M $344.99 602
2018 Q1 72M $24.8B +$207M $344.36 601
2017 Q4 71.1M $26.7B -$476M $375.96 617
2017 Q3 71.9M $32.1B -$384M $447.12 590
2017 Q2 72.6M $35.7B +$1.28B $491.14 585
2017 Q1 71.5M $27.7B +$2.46B $387.51 564
2016 Q4 71.8M $26.3B -$645M $367.09 564
2016 Q3 72.8M $29.2B +$504M $402.02 543
2016 Q2 71.6M $25B -$370M $349.23 531
2016 Q1 71.7M $25.8B -$143M $360.44 536
2015 Q4 72.8M $39.5B -$22.6M $542.87 566
2015 Q3 73M $34B -$197M $465.14 550
2015 Q2 72.9M $37.2B +$405M $510.13 531
2015 Q1 73M $32.9B +$441M $451.48 502
2014 Q4 72M $29.6B +$118M $410.25 504
2014 Q3 71.6M $25.8B -$605M $360.52 470
2014 Q2 73.4M $20.7B -$13.5M $282.47 444
2014 Q1 73.4M $22B -$741M $300.28 448